Bioxcel patents expiration
1. Igalmi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11786508 | BIOXCEL | Use of sublingual dexmedetomidine for the treatment of agitation |
Dec, 2037
(14 years from now) | |
| US11497711 | BIOXCEL | NA |
Jun, 2039
(15 years from now) | |
| US10792246 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US11517524 | BIOXCEL | NA |
Jun, 2039
(15 years from now) | |
| US11478422 | BIOXCEL | Film formulations containing dexmedetomidine and methods of producing them |
Jun, 2039
(15 years from now) | |
| US11806334 | BIOXCEL | Non-sedating dexmedetomidine treatment regimens |
Jan, 2043
(19 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product (NP) | Apr 5, 2025 |
Drugs and Companies using DEXMEDETOMIDINE HYDROCHLORIDE ingredient
Market Authorisation Date: 05 April, 2022
Treatment: Acute treatment of agitation associated with schizophrenia by sublingual or buccal administration; Acute treatment of agitation associated with schizophrenia or bipolar i or ii disorder by sublingual ...
Dosage: FILM;BUCCAL, SUBLINGUAL
More Information on Dosage
IGALMI family patents
